Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound.
Alzheon completed a $10 million Series A round of financing in April 2015 and has started a Phase I clinical trial for ALZ-801.
As quoted from biospace.com. Read the full article here